Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study

Fig. 1

Mean (SD) change from baseline in frequency of headache days. Mean (SD) change from baseline in frequency of headache days. Patient-reported estimated number of days per month with a headache (≥ 4 h) at each administration visit 1 through 8. Patients treated with (a) 155 U onabotulinumtoxinA or (b) 156 U – 195 U at 4 or more visits. * p < 0.001 paired t- test for change vs baseline. h, hours; SD, standard deviation; U, units

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us